Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
165,547,872
-
Number of holders
-
106
-
Total 13F shares, excl. options
-
54,342,875
-
Shares change
-
+439,070
-
Total reported value, excl. options
-
$235,299,521
-
Value change
-
-$5,313,006
-
Put/Call ratio
-
1.38%
-
Number of buys
-
41
-
Number of sells
-
-67
-
Price
-
$4.33
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q4 2021
134 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q4 2021.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 106 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54,342,875 shares
of 165,547,872 outstanding shares and own 32.83% of the company stock.
Largest 10 shareholders include Point72 Asset Management, L.P. (6,303,025 shares), RTW INVESTMENTS, LP (6,029,700 shares), BVF INC/IL (5,803,700 shares), VANGUARD GROUP INC (5,107,991 shares), BlackRock Inc. (4,962,362 shares), ORBIMED ADVISORS LLC (3,214,509 shares), STATE STREET CORP (2,739,544 shares), Rubric Capital Management LP (2,406,449 shares), Candriam Luxembourg S.C.A. (1,760,812 shares), and MILLENNIUM MANAGEMENT LLC (1,266,922 shares).
This table shows the top 106 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.